At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 99 enrolled
Drug / intervention
Lanreotide autogel 120 mgdrug
Likely dose
Lanreotide autogel 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days
In Brief
A Phase 2 clinical trial evaluating Lanreotide autogel 120 mg for Pancreatic Tumours and Midgut Neuroendocrine Tumours. Completed, enrolled 99 participants across 32 sites in 10 countries.
Detailed Summary
This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Tumours, Midgut Neuroendocrine Tumours
CountriesBelgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Poland, Spain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedJan 2016
Primary CompletionOct 2019
Study CompletionOct 2019
TodayJul 2026
First PostedJan 11, 2016
Enrollment StartDec 15, 2015
Primary CompletionOct 16, 2019
Study CompletionOct 24, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 10.5 years ago
Interventions
Lanreotide autogel 120 mgdrug